Stay updated with breaking news from Prostatype Genomic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics....
Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype®, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately.
Prostatype Genomics and Life Genomics start a non-exclusive collaboration meaning Life Genomics will handle all steps in the laboratory process required to analyse Prostatype®, Prostatype Genomics' gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype® from patients and healthcare. The agreement applies to all Nordic countries and comes into force immediately.